Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous‐cell carcinoma of the larynx

To determine the relationship between p16MTS1/CDK4I expression, gene inactivation and 9p21 loss of heterozygosity (LOH) in the development of laryngeal carcinomas, we have examined p16MTS1/CDK4I protein and mRNA expression in a series of 7 normal and 36 tumoral tissues, and the presence of gene alterations and 9p21 LOH. Fifteen tumors (42%) showed low levels of p16MTS1/CDK4I protein expression (similar to normal samples), 7 carcinomas (19%) expressed higher levels, and no protein expression was seen in 14 tumors (39%). No gene alterations were detected in 11 of the 15 tumors (73%) with protein levels similar to normal tissues. Most of the cases with absence of protein expression (86%) had gene alterations. Of the 7 tumors with protein over‐expression, 4 showed frameshift or point mutations (2 cases each). mRNA analysis showed p16MTS1/CDK4I‐gene expression in 12 of 17 carcinomas examined. Gene alterations were detected in 9 of the 12 mRNA‐positive tumors and in 2 of the 5 negative carcinomas. Concordant expression of p16α and p16β transcripts was observed in all tumors. 9p21 LOH was detected in 23 carcinomas, 18 of which (78%) showed associated p16MTS1/CDK4I‐gene alterations. These results indicate that disregulation of p16MTS1/CDK4I protein and mRNA expression is a frequent phenomenon in laryngeal carcinomas commonly associated with gene alterations and 9p21 LOH. The relative number of discrepancies between protein and mRNA expression and the presence of genetic alterations indicate that a comprehensive study of the gene including all these parameters may be necessary to assess the role of this gene in the pathogenesis of such tumors. Int. J. Cancer 81:705–711, 1999. © 1999 Wiley‐Liss, Inc.

[1]  A. Huvos,et al.  Molecular support for field cancerization in the head and neck , 1998, Cancer.

[2]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[3]  A. El‐Naggar,et al.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. , 1997, The American journal of pathology.

[4]  P. Pollock,et al.  CDKN2A/p16 is inactivated in most melanoma cell lines. , 1997, Cancer research.

[5]  P. Waber,et al.  Genetic alterations of chromosome band 9p21 – 22 in head and neck cancer are not restricted to p16INK4a , 1997, Oncogene.

[6]  E. Campo,et al.  p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx , 1997, The Journal of pathology.

[7]  E. Campo,et al.  p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx , 1997, Oncogene.

[8]  G. Mann,et al.  Differential expression of p16INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations , 1997, Oncogene.

[9]  A. Olshan,et al.  Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV , 1997, Oncogene.

[10]  M. Imamura,et al.  Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous‐cell‐carcinoma cell lines , 1997, International journal of cancer.

[11]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[12]  S. Nishizuka,et al.  Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. , 1996, Cancer research.

[13]  S. Hirohashi,et al.  Inactivation of p16INK4 in hepatocellular carcinoma , 1996, Hepatology.

[14]  J. Bartek,et al.  High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. , 1996, Cancer research.

[15]  A. Fusco,et al.  Status and expression of the p16INK4 gene in human thyroid tumors and thyroid‐tumor cell lines , 1996, International journal of cancer.

[16]  G. Peters,et al.  Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence , 1996, Molecular and cellular biology.

[17]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[18]  A. Balmain,et al.  Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. , 1995, Cancer research.

[19]  J. Field,et al.  Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. , 1995, Oncogene.

[20]  X. Estivill,et al.  Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. , 1995, American journal of human genetics.

[21]  S. Tavtigian,et al.  Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.

[22]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[23]  J. Batsakis,et al.  Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. , 1995, Cancer research.

[24]  R. Chaganti,et al.  Homozygous Deletions and Loss of Expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors , 1995, Genes, chromosomes & cancer.

[25]  W Arap,et al.  Loss of P16INK4 expression is frequent in high grade gliomas. , 1995, Cancer research.

[26]  Bonnie F. Sloane,et al.  Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. , 1994, The American journal of pathology.

[27]  A. Okamoto,et al.  Mutations and altered expression of p16INK4 in human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Klein-Szanto,et al.  Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. , 1994, Cancer research.

[29]  F. Bosch,et al.  PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. , 1994, Cancer research.

[30]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[31]  R. Hruban,et al.  Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. , 1994, Cancer research.

[32]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[33]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.